Piper Jaffray Companies Message Board
-
Free $$$$$$$$$$$$$$$$$$$$$$$ at the current price.
-
"A fool and his money is soon parted."
$30.00 by the end of the year. -
Cover before the open.
-
Dendreon type squeeze ahead.
-
They're going to burn. :(
-
Belviq wasn't going to get approved in Europe prior to the U.S. launch. A successful track record of sales and usage in the U.S. plus an European partner such as Sanofi will get Belviq approved.
This is still one press release away from $12.00.
Add a few shares before the launch.
"Patience is a virtue." -
Not if but when.
Dendreon went from $5.00 to $57.00. -
WCoastGuynCA @WCoastGuynCA
@adamfeuerstein With 65,000,000 shares short how much higher than $12.00 will $ARNA's share price be when Belviq launches? On E.U. approval? -
Read the recent Yahoo news.
-
.25 by May 1.
-
.15 by April 16.
Told you to buy it yesterday at the open. -
You can't really be this stupid can you?
-
Buy a few shares at the open today.
Substantially undervalued. -
First revenue report expected next week.
-
Read today's Yahoo news regarding the company's MANF study data.
Get in today under a dime. -
Eisai buyout in the $30.00 range.
-
Dendreon type squeeze ahead.
DNDN went from $5.00 to $57.00. -
50% upside by April 1.
Belviq launch is overdue. - Reply to
March 18, 2013 Amarantus BioScience Appoints Mark Benedyk, Ph.D., to Board of Directors
by joelord57 •Mar 18, 2013 12:11 PMThe company continues to be joined by world class talented individuals.